Parathyroid Hormone and Heart Failure: Novel Biomarker Strategy

Author(s): Hakan Altay, Yucel Colkesen

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 13 , Issue 1 , 2013

Become EABM
Become Reviewer
Call for Editor


Heart failure (HF) is a clinical syndrome featuring cardiac pump failure along with signs and symptoms arising from salt and water retention mediated by activated renin-angiotensin-aldosterone system (RAAS). In addition to this cardiorenal perspective, HF is accompanied by a systemic illness, especially in advanced stages characterized by oxidative stress in various tissues, causing damage to soft tissue and bone. Secondary hyperparathyroidism (SHPT) which is also considered to contribute this systemic illness is therefore prominent in advanced HF. SHPT in HF occurs as a result of RAAS activation, prominent hyperaldosteronism, loop diuretic usage and decreased calcitriol level, all of which results in calcium excretion. We review the evidence that high parathyroid hormone (PTH) is associated with advanced HF, as well as evidence that it’s associated with HF with preserved ejection fraction (HFPEF).

Keywords: Biomarker, heart failure, parathyroid hormone.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 13 March, 2013
Page: [100 - 104]
Pages: 5
DOI: 10.2174/1871530311313010012

Article Metrics

PDF: 47